Zota Health Care Limited announced on February 4, 2026, the approval of its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The Board of Directors also approved the acquisition of 58,827 equity shares of its wholly-owned subsidiary, Davaindia Health Mart Limited, through a rights issue, for a consideration of ₹25.30 crore. Additionally, the company finalized the acquisition of 100% stake in Curexis Ventures Private Limited for ₹10 lakh, as previously intimated on January 30, 2026. The Board also approved the formation of a Risk Management Committee with Mr. Moxesh Ketanbhai Zota as Chairperson, Mr. Himanshu Muktilal Zota as Member, and Mr. Dhaval Chandubhai Patwa as Member. The financial results indicate that for the nine months ended December 31, 2025, Zota Health Care reported consolidated revenue from operations of ₹37,548.22 lakh and a profit after tax of ₹2,181.78 lakh. Standalone revenue from operations was ₹28,630.67 lakh with a profit after tax of ₹600.50 lakh.
